/ Print /

Drug costs

Opinion: Time to Manage ‘Clinically Superfluous’ Drug Products to Control CostsPBMs are in a unique position to leverage three critical tools to protect patients from unnecessary healthcare costs.
Seven Ways to Help Patients Access Costly Cancer DrugsTwo new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.
Is there a simple fix for the Part D discount program?A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.
Stem cell therapy shows promise for COPD, but questions remainAutologous stem cell therapy may offer hope for patients with COPD. But some say caution is necessary.
Five questions for CVS Health’s Troyen A. Brennan, MD, MPHCVS Health’s Troyen A. Brennan, MD, MPH, brings attention to a unique specialty pharmacy model and value-based contracting.
CMS plan to slash 340B payments under fire by hospitalsHere are four ways CMS’ final rule related to the 340B Drug Pricing Program could affect the healthcare industry.
Controversy heats up over pharmacy benefit manager DIR feesPBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.
When given the chance, will patients choose cheaper prescription drugs?A new UC Berkeley study has surprising findings about reference pricing and patient drug selection.
How to approach value in oncologyAn eye-opening study by Precision for Value assesses cancer value frameworks.
Top 3 factors in biosimilar coverageAn Avalere study has interesting findings about payer acceptance of biosimilars.